Selective TRAIL-induced cytotoxicity to lung cancer cells mediated by miRNA response elements

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Lung cancer remains a significant health challenge with limited effective treatments.
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy due to its potent apoptosis-inducing effects.
• TRAIL's clinical application is hindered by its toxicity to normal cells.

Purpose of the Study:

• To engineer a novel adenoviral vector for targeted TRAIL expression in lung cancer.
• To enhance the specificity of TRAIL-mediated apoptosis in cancer cells.
• To reduce the potential toxicity of TRAIL therapy in normal tissues.

Main Methods:

• Insertion of microRNA response elements (MREs) from miR-133a, miR-137, and miR-449a into an adenoviral vector to regulate TRAIL expression.
• Development of an MRE-regulated adenoviral vector (Ad-TRAIL-MRE) for lung cancer-specific TRAIL delivery.
• Evaluation of Ad-TRAIL-MRE's cytotoxicity, TRAIL expression, and in vivo efficacy in lung cancer models.

Main Results:

• Ad-TRAIL-MRE demonstrated lung cancer-specific TRAIL expression, with no detectable expression in normal cells.
• The vector selectively induced apoptosis and cytotoxicity in lung cancer cells but not in normal cells.
• In vivo studies confirmed selective tumor growth inhibition and minimal hepatotoxicity.

Conclusions:

• A novel MRE-regulated adenoviral vector (Ad-TRAIL-MRE) was successfully generated for targeted TRAIL delivery.
• This strategy enables lung cancer-specific TRAIL expression, offering a promising therapeutic approach.
• The Ad-TRAIL-MRE vector warrants further investigation for potential clinical trials in lung cancer treatment.